Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates

Blocking proprotein convertase subtilisin kexin type 9 (PCSK9) binding to low-density lipoprotein receptor (LDLR) can profoundly lower plasma LDL levels. Two anti-PCKS9 monoclonal antibodies (mAbs), alirocumab and evolocumab, were approved by the FDA in 2015. The recommended dose is 75 mg to 150 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yijun, Li, Hua, Zhao, Li, Li, Gang, Chen, Ben, Guo, Qingsong, Gao, Bei, Wu, Jinsong, Yang, Tong, Jin, Li, Su, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560549/
https://www.ncbi.nlm.nih.gov/pubmed/28817679
http://dx.doi.org/10.1371/journal.pone.0183326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560549/
https://www.ncbi.nlm.nih.gov/pubmed/28817679
http://dx.doi.org/10.1371/journal.pone.0183326

Ejemplares similares